Context Therapeutics has dosed the first subject in the Phase I trial of CTIM-76, targeting gynaecologic and testicular cancers.

Their conclusion that the Biden administration overestimated the risk of escalation underestimates just how hard it is to ...

Your feelings tell you a lot about who you are, what you want, and what to do. The key is to learn how to sit with your ...

Around the world, feminist activists have successfully combated autocracy — most recently in South Korea. U.S. grant makers ...

All leaders have the same basic goal: to make things better and more efficient, and to help the people they lead perform at ...

Verismo Therapeutics has commenced the first patient dosing in its multicentre Phase I CELESTIAL-301 trial of SynKIR-310.

For their sample, the first-year experience suggests that auto-enrollment increased the savings rate by 2.2 percentage points (see Figure 1). (For simplicity, this discussion focuses on ...

SAN CARLOS, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next-generation, potentially curative cell ...

Auto-enrollment will increase the contribution rate of those who would never have joined the plan and those who would have joined at a lower rate, but will decrease contributions of those who would ...